Meeting Overview | We are pleased to invite you to the Expert PracticeSM in Metastatic Breast Cancer meeting in Frankfurt, Germany, on 21 May 2011.
During this case-based meeting, leaders in the field discuss with participants, in an interactive format, clinical issues encountered daily by practicing physicians.
This meeting is restricted to healthcare professionals based outside of the United States. You will be asked to provide your credentials to register.
For available travel grants, please contact: travelgrants@prIMEoncology.org. |
Location | Le Méridien Parkhotel Frankfurt
Wiesenhüttenplatz 28-38
60329 Frankfurt am Main, Germany |
Target Audience | This educational activity is designed for Pan-European medical oncologists, radiation oncologists, surgical oncologists, and other healthcare providers actively involved in the management of patients with breast cancer. This meeting is restricted to healthcare professionals based outside of the United States. |
Learning Objectives |
- Evaluate currently approved and available treatment options for patients with metastatic breast cancer, commenting on the degree to which these strategies provide clinical benefit and affect quality of life
- Strategize potential solutions to overcome treatment barriers for patients with metastatic breast cancer who have failed multiple rounds of chemotherapy
- Summarize therapeutic options and clinical challenges in the management of patients with metastatic breast cancer and CNS metastases
- Discuss the role of discordant pathology results after rebiopsy of a metastasis and how these results may impact therapy selection
|
 Faculty |
| Chairman
Christian Jackisch, MD, PhD
Klinikum Offenbach
Offenbach, Germany
|
|
Moderator
Lee Lokey, MD
prIME Oncology
Atlanta, Georgia, United States
|
|
|
Faculty
Fabrice André, MD, PhD
Institute Gustave Roussy
Villejuif, France
|
|
|
Javier Cortés, MD, PhD
Vall d’Hebron University Hospital
Barcelona, Spain
|
|
Alessandra Gennari, MD, PhD
Galliera Hospital
Genoa, Italy
|
|
|
Agenda |
| Friday, 20 May |
|
| 20.00-22.00 |
Welcome reception and dinner
|
| Saturday, 21 May |
|
| 08.30 |
Welcome, introduction, and demographic questions
Chair and prIME Medical Director
|
| 08.50 |
Challenges and opportunities in metastatic breast cancer
Alessandra Gennari, MD, PhD
|
| 09.10 |
Case #1:
Metastatic endocrine-responsive cancer in a patient with good performance status
Fabrice André, MD, PhD
|
| 09.45 |
Case #2:
Management of metastatic disease after two previous lines of chemotherapy
Javier Cortés, MD, PhD
|
| 10.20 |
Break
|
| 10.40 |
Case #3:
Multidisciplinary management of brain metastases
Christian Jackisch, MD, PhD
|
| 11.15 |
Case #4:
Dealing with discordant pathology results after rebiopsy of a metastasis
All Faculty
|
| 11.50 |
Clinical opinion poll questions
|
| 12.20 |
Lunch
|
| 13.20 |
Case #5:
Metastatic HER2-amplified disease following adjuvant trastuzumab and chemotherapy
Javier Cortés, MD, PhD
|
| 13.55 |
Case #6:
Management of the elderly patient with comorbid illnesses
Alessandra Gennari, MD, PhD
|
| 14.30 |
Case #7:
Triple-negative breast cancer
Fabrice André, MD, PhD
|
| 15.05 |
Questions and faculty panel discussion
Christian Jackisch, MD, PhD and All Faculty
|
|
|
|
|
Downloadable Slides | Challenges and opportunities in metastatic breast cancer
Alessandra Gennari, MD, PhD
Case #1:
Metastatic endocrine-responsive cancer in a patient with good performance status
Fabrice André, MD, PhD
Case #2:
Management of metastatic disease after two previous lines of chemotherapy
Javier Cortés, MD, PhD
Case #3:
Multidisciplinary management of brain metastases
Christian Jackisch, MD, PhD
Case #5:
Metastatic HER2-amplified disease following adjuvant trastuzumab and chemotherapy
Javier Cortés, MD, PhD
Case #6:
Management of the elderly patient with comorbid illnesses
Alessandra Gennari, MD, PhD
Case #7:
Triple-negative breast cancer
Fabrice André, MD, PhD |
Accreditation | Expert PracticeSM in Metastatic Breast Cancer has been awarded the ESMO label and 5 ESMO-MORA Category 1 points. Participants will receive a certificate of attendance at the conclusion of the activity.
 |
Support | Support for this activity has been provided by Cephalon Oncology and Eisai Europe Limited.
|
Organizer | This meeting is a prIME Oncology activity.
|
|
